Product Information
Registration Status: ActiveSIN10727P
TRENLIN 400 SR TABLET 400mg is approved to be sold in Singapore with effective from 1999-08-02. It is marketed by DUOPHARMA (SINGAPORE) PTE LTD, with the registration number of SIN10727P.
This product contains Pentoxifylline 400mg in the form of TABLET, FILM-COATED. It is approved for ORAL use.
This product is manufactured by UPHA PHARMACEUTICAL MANUFACTURING (M) SDN BHD in MALAYSIA.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A methylxanthine derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. [PubChem]
Indication
For the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs.
Mechanism of Action
Pentoxifylline inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, pentoxifylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. It is also a non selective adenosine receptor antagonist.
Toxicity
LD50=1385 mg/kg(orally in mice)
Active Ingredient/Synonyms
Oxpentifylline | Pentoxifilina | Pentoxifyllin | Pentoxifylline | Pentoxifyllinum | Pentoxifylline |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.